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Background
The majority of lung cancer in the U.S. is treated in the
community. A prospective cohort study of stage IV
NSCLC and extensive disease (ED) SCLC is being con-
ducted in 70 U.S. community practices to assess outcomes
during the pre- and post-immunotherapy eras of lung
cancer treatment. This analysis focuses on characteristics
of the rarer SCLC subset in the pre-immunotherapy era.
Methods
ED SCLC patients, at any point in their care, with docu-
mented dates of diagnosis and prior treatment are eligible.
Patients are followed prospectively for 36 months or until
death, with data abstraction from medical records.
Archival tumor tissue (formalin-fixed paraffin-embedded)
slides are used to measure PD-L1 protein expression with
a validated, automated immunohistochemistry (IHC) assay
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Table 1 Summary of clinical attributes and PD-L1 Expression in SCLC
Characteristic Cohort PD-L1 (<1%) PD-L1 (≥1%) Frequency in PD-L1 ≥1% Fisher (pV)
Smoking status EVER 70 13 15.7%
NEVER 4 0 0.0% 1.00
Sex Male 40 6 13.0%
Female 34 7 17.1% 0.765
ECOG 0-1 49 7 12.5%
2-3 21 6 22.2% 0.335
Age <70 47 5 10%
≥70 27 8 23% 0.126
Autoimmune Disorders Present 4 3 42.9%
Absent 68 9 11.7% 0.057
Site of biopsy for PDL1 samples* Primary 37 6 14.0%
Metastatic 36 7 16.3%
Primary/Metastatic 1 0 0.0% 1.000
H&E – Tumor Tissue Inflammation* Absent 20 2 9.1%
Present 30 6 16.7% 0.6971
H&E – Tumor Tissue Necrosis Absent 31 3 8.8%
Present 19 5 20.8% 0.2254
H&E-% Intra-Tumoral Inflammatory Infiltrate* <10% 41 1 2.4%
≥10% 30 10 33.3% 0.003
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from Dako using the 28-8 antibody. Expression levels of
tumor cell membrane staining at any intensity were
defined for ≥1% and ≥ 5% of 100 assessable tumor cells.
Results
Data from 268 cases with complete records are reported.
At enrollment, 95% were ever smokers, 53% female, and
26% ECOG performance status (PS) 2 or 3. The most
prevalent sites of metastases were liver (34%), bone (32%),
and brain (21%). History of a specific autoimmune condi-
tion was present in 8% of cases. The median overall survi-
val from diagnosis with extensive disease will be reported.
PD-L1 IHC was performed on 96/268 patients with avail-
able tissue and was evaluable in 87/96 cases. PD-L1 was
expressed at ≥1% for 13 cases (15%) and ≥5% for 2 (2%)
cases. Of these, 85 had hematoxylin and eosin (H&E)
staining performed showing tumor inflammation in 62%
and tumor necrosis in 41% of cases. An intra-tumoral
inflammatory infiltrate of ≥10% was observed in 49%
of cases and is associated with PD-L1 expression at ≥1%
(P < 0.003).
Conclusion
Many immunotherapy clinical trials exclude patients with
active or untreated brain metastases and patients receiving
treatment for autoimmune disease, yet a substantial
proportion of community-based SCLC patients present
with these attributes. PD-L1 expression levels in SCLC
appear lower than those previously reported in NSCLC.
The role of PD-L1 and other tumor and blood-based
markers as prognostic or predictive for SCLC outcomes
will be investigated in this ongoing study.
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